Idecabtagene vicleucel (ide-cel, bb2121), a chimeric antigen receptor (CAR) T 
cell therapy, has been investigated in patients with relapsed and refractory 
multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome 
inhibitor, and anti-CD38 antibody in the single-arm phase 2 KarMMa clinical 
trial. Two therapies with distinct mechanisms of action - selinexor plus 
dexamethasone (Sd) and belantamab mafodotin (BM) - are currently approved in the 
United States for heavily pretreated patients, including those who are 
triple-class refractory. To compare ide-cel versus Sd and ide-cel versus BM, 
matching-adjusted indirect comparisons were performed. Ide-cel extended 
progression-free survival (PFS) and overall survival (OS) versus both Sd and BM 
(hazard ratio (HR); 95% confidence interval (CI)). PFS: ide-cel versus Sd, 0.46; 
0.28-0.75; ide-cel versus BM, 0.45; 0.27-0.77. OS: ide-cel versus Sd, 0.23; 
0.13-0.42; ide-cel versus BM, 0.35; 0.14-0.87. These results suggest ide-cel 
offers clinically meaningful improvements over currently approved regimens for 
patients with heavily pretreated RRMM.